Jilin Zixin Pharmaceutical
Industrial Co., Ltd.
Jilin Zixin Pharmaceutical Co., Ltd. (hereinafter referred to as “the company”) was established in May 1998. It is a core business of Chinese patent medicine industry, ginseng industry and gene sequencer industry. It is highly integrated with production, sales and scientific research. A high-tech group listed company that is a kind of medicinal animal and plant species breeding (listed on the Shenzhen Stock Exchange on March 2, 2007, the stock is referred to as “Zixin Pharmaceutical”, stock code is 002118).
The company has been in development for 20 years. At present, the company has 20 wholly-owned and controlled subsidiaries and Sun companies, and one shareholding financial company. They are located in the south, middle and east of the Changbai Mountains, Hong Kong, the United States, the Netherlands and other places. After more than a decade of rapid development, the scale of the company has continued to expand, and the value of profits and taxes has risen year after year. The company has been rated as a large taxpayer of non-public economy in Jilin Province; small giant enterprise; top 100 non-public ownership enterprises; national top 100 Chinese medicine enterprises; national high-tech enterprises; national youth civilization enterprises; national key agricultural industrialization leading enterprises It has gradually formed an integrated business model of large health industry chain with "Zixin characteristics".
TOP MANAGEMENT TEAM
Director General Manager
Director, Production Vice President Han Ming
Chairman Guo Chunlin
Director Financial Director
Supervisor Bai Yubiao
Supervisor Zhang Hongfa
Chairman of the Board of Directors Wang Renhou
Secretary of the Board
One of the five drugstores Scientific management procedures
Compliance with legal standards High quality raw materials
The quality of medicinal materials is the key to ensuring product efficacy. The company is located in the hinterland of Changbai Mountain, known as one of the "five drugstores." This place is with fertile land, no pollution, and more than 2,000 types of medicinal herbs. We planted important raw materials such as ginseng, epimedium, and Asarum here. We adopt a series of scientific management procedures in terms of selection, breeding, planting, weeding, fertilizing, harvesting, processing, and storage. The medicines we produce are free from excessive heavy metals and pesticide residues. And through the identification of traits, content determination and other tests, our raw materials meet the statutory standards, ensuring the high quality of medicinal raw materials.
We greatly promote the planting and breeding of medicinal plants and animals and
adopt the method combining the cooperation of “Farmer-Government-Company-Institute” to cultivate our own medicine bases. This not only solidly guarantees the
company's raw material supply and scientific research and development, but also
drives the development of local rural industrialization and provides thousands of job
opportunities for the surrounding areas.
Signed the ginseng industry strategic cooperation framework agreement and officially launched the ginseng genome project.
Entering the genetic sequencing industry.
Tonghua Zijin Pharmaceutical Co., Ltd. was established.
Completion of non-public offering of shares raised funds of 1.6 billion yuan.
Established a US subsidiary
Zixin Pharmaceuticals USA CORP.
Acquisition of FG, Institute of Rhineland University,
Royal Netherlands Institute of Applied Research.
Beijing Gene Sequencer Industrialization Base
Complete transfer, transfer.
Non-public issuance of shares, raising funds of 1 billion yuan, set up four major ginseng production and processing bases in Tonghua, Yanji, Lanshi and Dunhua.
Signed a research agreement withYale University on genetic sequencers.
The company has once again become the sole authorized support unit for the (ISO/TC249) plenary meeting.
Overweight investment gene
sequencer industry1 billion yuan.
Launched the five-year development strategy plan for ginseng industry (2018-2022),It is planned to reach 150 production values in the next five years.
Start the second non-public offering of shares.
Completed GMP national certification and changed its name to
“Jilin Zixin Pharmaceutical Co., Ltd.”
Listed on the Shenzhen Stock Exchange.
The Jilin Academy of Agricultural Sciences signed the "Industrial Cannabis Cooperation Research Agreement" with the company's wholly-owned subsidiary in the Netherlands, Fytagoras B.V. The two sides formally established a cooperative R&D relationship and carried out research and development of industrial cannabis.
Launched the “National Ginseng Germplasm
Resources Survey” project.
The company always adheres to the operating principle of “respecting knowledge, advocating science, excavating tradition, and innovating”. In addition, we have formulated effective systems and implementation procedures in terms of research and development incentive mechanism, talent resource allocation and technology management. As a production-oriented enterprise, we actively cultivate a corporate culture with our own characteristics. By organizing labor competitions, carrying out cultural and recreational activities, and selecting advanced models, we aim to establish employees' sense of ownership as companies and achieve the long-term integration of employees' interests and corporate interests.
Respecting knowledge, Advocating science, Excavating traditions, Innovating,
Cultivating people’s virtue, Producing drugs with professional ethics
In addition, we hope to use this to mobilize the enthusiasm and creativity of employees, create a united and uplifting environment, and enhance the company's affinity and cohesion. Through various methods such as on-the-job training and off-campus learning, we continue to strengthen the company's cultivation of talents for production and operation management, technology research and development to meet the urgent need for relevant talents in the company's rapid development. More than 14.07% of the company’s personnel have bachelor degree or above, and 16.86% or more have college education. Among these people, there are professional and technical talents in various fields such as certified public accountants, licensed pharmacists, and engineering and technical personnel.
The development and upgrading of products is the key to the rapid development of the company. Therefore, our company has established a scientific research system with the long-term goal of “production generation, reserve generation, and development generation”.
We will focus on the treatment of gastrointestinal and anti-depressant drugs to accelerate the development of biological agents and further develop single-taste drugs and sub-group varieties.
Our company accelerates the development of biological agents and further develop single-taste drugs and sub-group varieties. In addition, our focus will still be on the national class II and III western medicines to upgrade and redevelop existing key varieties.
At present, our company is investing heavily in the development of cardiovascular, sedative, and gynecological drugs. Combining the changes in modern disease groups, we have developed effective drugs for the treatment of cardiovascular diseases, endocrine disorders, liver diseases, and digestive system problems.
Combining the changes in modern disease groups, we have developed effective drugs for the treatment of cardiovascular diseases, endocrine disorders, liver diseases, and digestive system problems, which greatly helps to form a complete range of products with reasonable structure.